Last $953.00 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:08 PM 04/9/14 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX*) Snapshot

Open
$953.00
Previous Close
$953.00
Day High
$953.00
Day Low
$953.00
52 Week High
03/27/14 - $962.00
52 Week Low
05/7/13 - $823.00
Market Cap
515.5B
Average Volume 10 Days
310.6
EPS TTM
--
Shares Outstanding
540.9M
EX-Date
03/5/14
P/E TM
--
Dividend
$1.99
Dividend Yield
2.70%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX*)

baxter international inc (BAX*) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX*) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

61,000 Employees
Last Reported Date: 02/21/14
Founded in 1931

baxter international inc (BAX*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Int...
Total Annual Compensation: $771.2K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX*) Key Developments

Baxter International Inc. expected to report Q1 2014 results on April 16, 2014. This event was calculated by Capital IQ (Created on April 4, 2014).

Baxter International Inc. expected to report Q1 2014 results on April 16, 2014. This event was calculated by Capital IQ (Created on April 4, 2014).

Baxter International Plans To Spin Off Biopharma Business In 2015

Baxter International Inc. (NYSE:BAX) said that it would spin off its biopharmaceuticals business into a ublicly traded company by the middle of next year and focus on its core medical technology business. The corporate headquarters of both companies will be located in northern Illinois and Robert Parkinson, Jr., will be Chairman and Chief Executive Officer of the medical products company, retain the Baxter International name. Ludwig Hantson, who currently serves as President, BioScience, will be the Chief Executive of the new biopharmaceuticals company, which will be named at a later date.

Baxter International Inc. - Shareholder/Analyst Call

To discuss the creation of two separate companies

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX*:MM $953.00 MXN 0.00

BAX* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covidien PLC $69.84 USD -0.06
Danone SA €52.37 EUR -0.91
Kimberly-Clark Corp $112.41 USD +1.86
Takeda Pharmaceutical Co Ltd ¥4,546 JPY +18.00
Teva Pharmaceutical Industries Ltd $49.91 USD +0.30
View Industry Companies
 

Industry Analysis

BAX*

Industry Average

Valuation BAX* Industry Range
Price/Earnings 20.0x
Price/Sales 2.6x
Price/Book 4.7x
Price/Cash Flow 19.7x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.